Diamond B
Department of Microbiology & Immunology and Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Dev Biol (Basel). 2003;112:29-34.
As recombinant proteins join the physician's armamentarium to a larger and larger extent, the capacity of these "self" proteins to induce an immune response has become more widely appreciated. The most surprising observation has been that these proteins may induce an immune response even in an individual who is not deficient in the protein, but merely produces an insufficient amount for the desired biological effect. Furthermore, individuals with no apparent predisposition to auto-immunity mount antibody responses to these proteins. Fortunately, the antibody response often does not block the activity of the proteins and sometimes the response may even disappear over time. Nevertheless, the immunogenicity of human recombinant proteins is a significant limitation in their use. This review first reviews aspects of B cell tolerance and activation and then presents a model to try to explain the auto-immune response to therapeutic proteins.
随着重组蛋白在医生的治疗手段中所占比例越来越大,这些“自身”蛋白诱导免疫反应的能力已得到更广泛的认识。最令人惊讶的发现是,这些蛋白甚至可能在并非缺乏该蛋白、只是产生的量不足以达到所需生物学效应的个体中诱导免疫反应。此外,没有明显自身免疫倾向的个体也会对这些蛋白产生抗体反应。幸运的是,抗体反应通常不会阻断蛋白的活性,有时这种反应甚至会随着时间消失。然而,人重组蛋白的免疫原性是其应用中的一个重大限制。本综述首先回顾B细胞耐受和激活的相关方面,然后提出一个模型来试图解释对治疗性蛋白的自身免疫反应。